News & Updates
Showing Oncology articles
Showing
Show Multimedia Only
Ribociclib plus letrozole improves OS in hormone receptor–positive, HER2-negative advanced breast cancer
27 Sep 2021
byDr Margaret Shi
A combined regimen of ribociclib plus letrozole as first-line treatment provides a statistically significant and clinically meaningful overall survival (OS) benefit vs placebo plus letrozole in postmenopausal patients with hormone receptor–positive and HER2-negative advanced breast cancer (BC), results of the phase III MONALEESA-2 study have shown.